INDIANAPOLIS (AP) — A possible Alzheimer's disease treatment from drugmaker Eli Lilly showed some promise in late-stage research, even though the drug failed to slow a form of mental decline in two separate studies of patients with the mind-robbing condition.
Shares of the Lilly climbed Friday in morning trading after the Indianapolis company announced what could be a step toward a long-awaited breakthrough in the fight against a disease that has no cure and ultimately proves fatal. But Lilly officials cautioned that it's important not to overreact to their initial results.
Lilly said Friday its treatment, solanezumab, failed to slow cognitive decline, which involves a person's memory, in two late-stage studies of about 1,000 patients each. But when data from the trials were combined, scientists saw a statistically significant slowing of the rate of cognitive decline in the bigger population.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
